SWITZERLAND —Swiss market expansion services provider DKSH has signed a definitive agreement to acquire 100 percent of Dubai-based NewBridge Pharmaceuticals for an enterprise value of USD 390 million. The transaction establishes a regional healthcare platform spanning 14 markets in the Middle East and North Africa region, anchored by operations in the United Arab Emirates and the Kingdom of Saudi Arabia. Founded in 2010, NewBridge Pharmaceuticals is a commercialization platform specializing in biopharmaceutical products across oncology, neurology, immunology, gastroenterology, and rare disease therapeutics. The business maintains established networks across regional healthcare ecosystems through specialized market access, medical affairs, and sales infrastructure.
The transaction aligns with corporate strategies to expand operational footprints beyond the Asia Pacific region and scale capabilities within higher-margin commercial outsourcing segments. By integrating the target's regional platform, the acquirer positions its healthcare division to capture structural growth driven by rising demand for localized commercialization partners and supportive regulatory frameworks. Financial projections indicate the acquired operations will contribute approximately USD 385 million in net sales during 2027, accompanied by high single-digit EBITDA margins. The acquisition is structured to remain earnings-per-share accretive from closing while maintaining debt financing headroom for future capital deployment and existing dividend policies.
The transaction carries significant implications for pharmaceutical developers, regional healthcare providers, and international biotech enterprises seeking unified commercialization partners across multiple emerging territories. Biopharmaceutical firms operating in specialized therapeutic categories face complex regulatory, distribution, and market access hurdles across fragmented Middle Eastern jurisdictions. Consolidating commercial outsourcing through a single multinational platform simplifies regulatory navigation, accelerates product launches, and expands patient access to advanced therapies. Furthermore, the integration of specialized medical affairs and sales forces provides smaller biotechnology companies with scalable market entry mechanisms without requiring direct capital expenditure for local infrastructure.
From an investor and market perspective, the transaction reflects ongoing consolidation trends within international commercial outsourcing and cross-border healthcare services. Market participants monitor such cross-regional expansions to gauge corporate resilience against shifting macroeconomic conditions and supply chain complexities. Financial markets will track the integration timeline, execution of projected net sales targets, and subsequent realization of operating synergies through the end of the first quarter of 2027, pending customary regulatory approvals and closing conditions.
DKSH Holding Ltd is a Swiss market expansion services provider established over 160 years ago, operating across business units including healthcare, consumer goods, performance materials, and technology. The company employs thousands of specialists globally, distributing pharmaceuticals, consumer health items, and medical devices across multiple international markets.
